Epiretinal Membrane and Cystoid Macular Oedema Post-cataract Surgery

Launched by PORTSMOUTH HOSPITALS NHS TRUST · May 24, 2019

Keywords

ClinConnect Summary

Cataract surgery is the most frequently performed surgery in the NHS. Cystoid macular oedema (CMO, inflammation and fluid accumulation in the central retina) is the most common visually significant complication following cataract surgery occurring in 1-2% of cases. Many cases resolve with topical anti-inflammatory eye drops. However some cases do not respond and require more invasive treatment modalities eg injections into the eye. If CMO remains persistent this can lead to permanent visual loss. There is little current knowledge on what factors lead to persistence in some cases compared to...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or Female, aged 18 years or above.
• • 2. Clinical diagnosis of visually significant pseudophakic CMO in ipsilateral eye within 12 weeks of cataract surgery.
• • The clinical diagnosis needs to be made by an ophthalmologist of Grade ST3 or higher.
• • Visually significant is defined as best recorded visual acuity 6/9 Snellen or worse (or LogMAR equivalent)
• • 3. An OCT has to have been undertaken and needs to show the presence of intra-retinal cysts and OCT thickness (central subfield CSF) outside normal parameters as defined by Grover et al \[12\] and Wolf-Schnurrbusch at al \[13\] (For clarity the OCT examination does not need to be undertaken on the same day as the clinical diagnosis of pseudophakic CMO. Any OCT examination undertaken after cataract surgery to the ipsilateral eye within the treatment period showing these characteristics will be acceptable to substantiate the clinical diagnosis of pseudophakic CMO.
• • 4. Started on treatment for cystoid macular oedema
• • 5. Participant is willing and able to give informed consent for participation in the study
• Exclusion Criteria:
• The participant may not enter the study if there is evidence that macular oedema may have been present pre-operatively. This will include ANY of the following:
• • Evidence of pre-existing macular fluid/oedema
• • Active proliferative diabetic retinopathy
• • Diabetic macular oedema requiring treatment in the last 2 years
• • Active uveitis at the time of cataract surgery
• • Neovascular age-related macular degeneration
• • Active retinal vein occlusion (branch or central) as evidenced by the presence of retinal haemorrhages at the time of cataract surgery or at time of diagnosis of CMO